Modification of doxorubicin-induced cardiotoxicity

effect of essential fatty acids and ICRF-187 (dexrazoxane)


      The capacity of an oil, containing gamma-linolenic acid (GLA), to reduce the severity of doxorubicin-induced cardiotoxicity has been investigated in a rat model. Groups of 12-week-old, male, Sprague–Dawley rats were injected intravenously (i.v.) with single doses (3 mg/kg body weight) of doxorubicin (DOX). Daily for 1 week prior to DOX administration and for up to 20 weeks afterwards groups of rats received either an oil containing both GLA and linoleic acid (So-1100, Scotia Pharmaceuticals), at two dose levels, or an oil containing linoleic acid, but no GLA (So-1129) by oral gavage. Other groups of rats received water as a control. One of the groups of rats that received water also received i.v. ICRF-187 (60 mg/kg) 15 min prior to DOX. A group of animals acted as age-matched controls. The maximum reduction in body weight in the first 2 weeks after the administration of DOX. was used as a measure of acute toxicity. This was most severe in the group receiving a combination of DOX and ICRF-187 (5.6±0.43%). Animals receiving 2 ml of either So-1100 or So-1129 were the least affected (≈2.5%). Measurements of cardiac volume output made at various intervals after DOX administration indicated a ≈35% reduction in cardiac function in the control and So-1129 oil group after 20 weeks. The corresponding reduction in the groups receiving ICRF-187 and 2 ml of So-1100 was ≈16%. The group receiving daily doses of 1 ml So-1100 showed an intermediate response. The death of an animal with signs of congestive cardiac failure occurred in 40% of the animals in the DOX only control (water) group. There were no deaths in the groups of rats receiving either ICRF-187 or pre- and post-administration of 2 ml of So-1100. It was concluded that an oil containing GLA (So-1100) has similar cardioprotective properties against DOX-induced cardiotoxicity as ICRF-187, but with less general toxicity in this rat model.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Von Hoff D.D
        • Rozencweig M
        • Layard M.V.V
        • Slavik M
        • Muggia F.M
        Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
        Am. J. Med. 1977; 62: 200-208
        • Von Hoff D.D
        • Layard M.V.V
        • Basa P
        • et al.
        Risk factors for doxorubici-induced congestive heart failure.
        Ann. Intern. Med. 1979; 91: 710-717
        • Sorenson K
        • Levitt G
        • Sebag-Montefiore D
        • Bull C
        • Sullivan I
        Cardiac function in Wilms' tumour survivors.
        J. Clin. Oncol. 1995; 13: 1546-1556
        • Steinberg L.J
        • Steinberg P.G
        • Tan C.T.C
        • Heller G
        • Murphy L
        Cardiac toxicity, 4 to 20 years after completing anthracycline therapy.
        JAMA. 1991; 266: 1672-1677
        • Billingham M.E
        • Mason J.W
        • Bristow B.J
        • Daniels J.R
        Anthracycline cardiomyopathy monitored by morphological changes.
        Cancer Treat. Rep. 1978; 62: 865-872
        • Bertazzoli C
        • Bellini O
        • Magrini U
        • Toscana M.G
        Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.
        Cancer Treat. Rep. 1979; 63: 1877
        • Basser R.L
        • Green M.D
        Strategies for the prevention of anthracycline cardiotoxicity.
        Cancer Treat. Rev. 1993; 19: 57-77
        • Keizer H.G
        • Pinedo H.M
        • Schuurhuis G.J
        • Joenje H
        Doxorubicin (adriamycin).
        Pharmacol. Ther. 1990; 47: 219-231
        • Myers C.E
        • MacGuire W.P
        • Liss R.H
        • Ifrim I
        • Grozinger R
        • Young R.C
        Science. 1977; 197: 165-167
        • Doroshow J.H
        • Locker G.Y
        • Myers C.E
        Enzymatic defences of the mouse heart against reactive oxygen metabolites.
        J. Clin. Invest. 1980; 65: 128-135
        • Creighton A.M
        • Hellman K
        • Whitecross S
        Antitumour activity in a series of bisdiketopiperazines.
        Nature. 1969; 222: 384-385
        • Hasinoff B.B
        The interaction of the cardioprotective agent ICRF-187 [(+/−)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane]; its hydrolysis product (ICRF-198) and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin.
        Agents Actions. 1989; 26: 378-385
        • Sobol M.M
        • Amiet R.G
        • Green M.D
        In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+/−)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane] onto an existing ferric–anthracycline complex.
        Mol. Pharmacol. 1991; 41: 8-17
        • Herman E
        • Ardalan B
        • Bier C
        • Waravdekar V
        • Krop S
        Reduction of daunomycin lethality and myocardial cellular alterations by pre-treatment with ICRF-187 in syrian golden hamsters.
        Cancer Treat. Rep. 1979; 63: 89-92
        • Herman E.H
        • Ferrans V.J
        Reduction of chronic daunorubicin cardiotoxicity in dogs pre-treated with (+/−)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187).
        Cancer Res. 1981; 41: 3436-3440
        • Herman E.H
        • Ferrans V.J
        • Jordan W
        • Ardalan B
        Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
        Res. Comm. Chemother. Pathol. Pharmacol. 1981; 31: 85-97
        • Yeung T.K
        • Jaenke R.S
        • Wilding D
        • Creighton A.M
        • Hopewell J.W
        The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
        Cancer Chemother. Pharmacol. 1992; 30: 58-64
        • Speyer J.L
        • Green M.D
        • Kramer E
        • et al.
        Protective effect of bispiperazinedione ICRF-187 against Doxorubicin-induced cardiotoxicity in women with advanced breast cancer.
        N. Engl. J. Med. 1988; 319: 745-752
        • Wexler L.H
        • Andrich M.P
        • Venzo D
        • et al.
        Randomised trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
        J. Clin. Oncol. 1996; 14: 362-372
        • Lipshultz S.E
        Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
        J. Clin. Oncol. 1996; 14: 328-330
        • Marcel Y.L
        • Christensen K
        • Holman R.T
        The preffer metabolic pathway from linoleic acid to arachidonic acid, in vivo.
        Biochim. Biophys. Acta. 1968; 16: 25-34
        • Horrobin D.F
        Nutritional and medical importance of gamma-linolenic acid.
        Prog. Lipid Res. 1992; 31: 163-194
        • Hopewell J.W
        • Robbins M.E.C
        • van den Aardweg G.J.M.J
        • Morris G.M
        • Ross G.A
        • Whitehouse E
        • Horrobin D.F
        • Scott C.A
        The modulation of radiation-induced damage to pig skin by essential fatty acids.
        Br. J. Cancer. 1993; 68: 1-7
        • Hopewell J.W
        • van den Aardweg G.J.M.J
        • Morris G.M
        • et al.
        Unsaturated lipids as modulators of radiation damage in normal tissues.
        in: Horrobin D.F New Approaches to Cancer Treatment: Unsaturated Lipids and Photodynamic Therapy. Churchill Communication, London1994: 88-108
        • Hopewell J.W
        • van den Aardweg G.J.M.J
        • Morris G.M
        • et al.
        Amelioration of both early and late radiation-induced damage to pig skin by essential fatty acids.
        Int. J. Radiat. Oncol. Biol. Phys. 1994; 30: 1119-1125
        • El-Agamawi A.Y
        • Hopewell J.W
        • Plowman P.N
        • Rezvani M
        • Wilding D
        Modulation of normal tissue responses to radiation.
        Br. J. Radiol. 1996; 68: 374-375
      1. Hopewell JW, Calvo W, Jaenke RS, Reinhold HS, Robbins MEC, Whitehouse EM. Microvasculature and radiation damage. In Hinkelbein WG, Bruggmoser W, Frommhold H, Wannermacher M, eds. Acute and Long-term Side-effects of Radiotherapy. Rec Res Cancer Res 1993, 130, 1–16.

        • Ziboh V.A
        • Yun M
        • Hyde D.M
        • Giri S.N
        Gamma-linolenic acid containing diet attenuates bleomycin-induced lung fibrosis in hamsters.
        Lipids. 1997; 32: 759-767
        • Das U.N
        Gamma-linolenic acid, arachidonic acid and eicosapentaenoic acid as potential anti-cancer drugs.
        Nutrition. 1990; 6: 428-434
        • Begin M.E
        • Ells G
        • Horrobin D.F
        Polyunsaturated fatty acid-induced cytotoxicity against tumour cells and its relation to lipid peroxidation.
        J. Natl. Can. Inst. 1988; 80: 188-194
      2. Horrobin DF. Unsaturated lipids and cancer. In: Horrobin DF, ed. New Approaches to Cancer Treatment: Unsaturated Lipids and Photodynamic Therapy. London, Churchill Communications, 3–29.

        • Yeung T.K
        • Hopewell J.W
        • Simmonds R.H
        • et al.
        Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl) ethracrylamide conjugates.
        Cancer Chemother. Pharmacol. 1991; 29: 105-111
        • Yeung T.K
        • Simmonds R.H
        • Hopewell J.W
        A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat.
        Radiother. Oncol. 1989; 15: 275-284
        • Yeung T.K
        • Hopewell J.W
        Effects of single doses of radiation on cardiac function in the rat.
        Radiother. Oncol. 1985; 3: 339-345
        • Yeung T.K
        • Simmonds R.H
        • Hopewell J.W
        Time- and dose-related changes in cardiac function in rats after single intravenous doses of epirubicin.
        Radiother. Oncol. 1988; 11: 263-269
        • Holcenberg J.S
        • Tutsch K.D
        • Earhart R.H
        • et al.
        Phase I study of ICRF 187 in pediatric cancer patients and comparison of its pharmcokinetics in children and adults.
        Cancer Treat. Rep. 1986; 70: 703-709
        • Hornsey S
        • Myers R
        • Jenkinson T
        The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs.
        Int. J. Radiat. Oncol. Biol. Phys. 1990; 18: 1437-1442
        • Yeung T.K
        • Simmonds R.H
        • Hopewell J.W
        The relative toxicity of intravenous and intraperitaneal doses of epirubicin.
        Cancer Chemother. Pharmacol. 1989; 24: 211-218
        • Jaenke R.S
        Delayed and progressive myocardial lesions after Adriamycine administration in the rabbit.
        Cancer Res. 1976; 36: 2958-2966
        • Bertani T
        • Poggi A
        • Pozzoni R
        • et al.
        Adriamycin-induced nephrotic syndrome in rats.
        Lab. Invest. 1982; 46: 16-23
        • Kitahara T
        • Liu K
        • Solanki K
        • Trott K.R
        Functional and morphological damage after local heart irradiation and/or adriamycin in Wistar rats.
        Radiat. Oncol. Invest. 1993; 1: 198-205
        • Van Hoesel Q.G.C.M
        • Steerenberg P.A
        • Dormans J.A.M.A
        • de Jong W.H
        • de Wildt D.J
        • Vos J.G
        Time-course study on doxorubicin-induced nephropathy and cardiopathy in male and female LOU/M/Wsl rats.
        J. Natl. Cancer Inst. 1986; 76: 299-307